Aromatic dicationic compounds possess antimicrobial activity against a wide range of eucaryotic pathogens, and in the present study an examination of the structures-functions of a series of compounds against fungi was performed. Sixty-seven dicationic molecules were screened for their inhibitory and fungicidal activities against Candida albicans and Cryptococcus neoformans. The MICs of a large number of compounds were comparable to those of the standard antifungal drugs amphotericin B and fluconazole. Unlike fluconazole, potent inhibitory compounds in this series were found to have excellent fungicidal activities. The MIC of one of the most potent compounds against C. albicans was 0.39 g/ml, and it was the most potent compound against C. neoformans (MIC, <0.09 g/ml). Selected compounds were also found to be active against Aspergillus fumigatus, Fusarium solani, Candida species other than C. albicans, and fluconazole-resistant strains of C. albicans and C. neoformans. Since some of these compounds have been safely given to animals, these classes of molecules have the potential to be developed as antifungal agents.
yields of 75 to 85%. The free base was converted to its HCl salt by treating the free base with saturated ethanolic-HCl, with yields of 75 to 90%.
2,5-Bis-{4-[3-(N-morpholinopropyl)carbamoyl]phenyl}furan dihydrochloride (compound 33
). An 83% yield of a yellow crystalline solid (mp, 140 to 142°C decompose [dec] ) was obtained by the procedure described above. 
2,5-Bis[4-(2-N,N-dimethylaminoethylcarbamoyl)phenyl]furan dihydrochloride (compound 34
). An 80% yield of pale yellow crystalline solid (mp, 189 to 191°C dec) was obtained by the procedure described above. 1 
2,5-Bis[4-(3-N,N-dimethylaminopropylcarbamoyl)phenyl]furan dihydrochloride (compound 35).
A 75% yield of yellow hygroscopic solid (mp, 205 to 208°C dec) was obtained by the procedure described above. 1 
2,5-Bis[3-amidinophenyl]furan dihydrochloride (compound 38).
A suspension of the imidate ester dihydrochloride (0.87 g, 0.002 mol), prepared from 2,5-bis [3-cyanophenyl] furan (31) , in 30 ml of absolute ethanol was saturated with dry ammonia at 0 to 5°C, and the mixture was stirred at room temperature for 2 h. The solvent was removed; the solid was treated with ice water, filtered, and basified with cold aqueous 2 M NaOH; and the off-white precipitate which formed was filtered. The solid was washed with water and dried to yield 0.49 g (80.6%; mp, 198 to 200°C). The free base (0.3 g, 0.001 mol) was converted into the HCl salt by treating it with ethanolic HCl to yield 0.35 g (90%; mp 221 to 224°C dec). 1 (31) , and isopropyl amine (0.124 g, 0.0022 mol) in 10 ml of ethanol were stirred for 12 h and yielded, after standard workup, 0.13 g (80%) of beige free base (mp, 180 to 181°C; crystallized from hexane-ether [3:1] 
2,5-Bis-3[(N-(2-dimethylaminoethyl)amidino]phenylfuran dihydrochloride (compound 41).
A mixture of imidate ester hydrochloride (0.435 g, 0.001 mol), prepared from 2,5-bis [3-cyanophenyl] furan (31), and 2-dimethylaminoethylamine (0.185 g, 0.0021 mol) in 10 ml of ethanol was stirred at room temperature for 12 h. On standard workup 0.33 g (74%) of crystalline solid (mp, 75 to 77°C) was obtained. On treatment with saturated ethanolic HCl, the free base (0.30 g, 0.00072 mol) gave 0.35 g (82%) hydrochloride salt (very hygroscopic), which was dried at 75°C for 24 h (mp, 260 to 263°C dec). 1 Medium. Antifungal susceptibility testing was performed in RPMI 1640 medium (Sigma, St. Louis, Mo.) with glutamine but without sodium bicarbonate and buffered at pH 7.0 with 0.165 M morpholinopropanesulfonic acid.
In vitro susceptibility testing. Experiments for determination of MICs were performed by the broth macrodilution method following the recommendations of the National Committee for Clinical Laboratory Standards (21) . The only difference compared to the standardized method was the choice of drug dilutions, which ranged from 100 to 0.09 g/ml. Briefly, this method specifies the use of an inoculum grown at 35°C and adjusted to a concentration of 0.5 ϫ 10 3 to 2 ϫ 10 3 CFU/ml, incubation at 35°C, and reading of the endpoints at 48 h for all yeasts other than C. neoformans, for which the endpoints are read at 72 h. The MIC was defined as the lowest drug concentration which produced a visual turbidity indicating less than or equal to 80% inhibition compared with that in the growth control tube.
Experiments for determination of MFCs were performed by a method adapted from that of McGinnis (20) . Briefly, 10-l aliquots from tubes with growth inhibition were plated onto Sabouraud agar plates. The lowest drug concentration that yielded three or fewer yeasts colonies was recorded as the MFC. Several drugs were also rescreened by subculturing 100-l aliquots from tubes with no growth, and there was no change in the MFCs.
Molds were tested by the same method (21) but with the following modifications. Isolates were grown on Sabouraud dextrose agar at 30°C and were subcultured twice to ensure viability. After adequate sporulation occurred (after 4 to 12 days), the conidia were harvested by flooding the colonies with a sterile solution of 0.85% NaCl-0.05% Tween 80 in distilled water. Inoculum suspensions were prepared by a hemocytometric procedure and were then diluted with RPMI 1640 medium to obtain an inoculum size of approximately 0.5 ϫ 10 3 to 2 ϫ 10 3 CFU/ml. The inoculum size was verified by plating an aliquot of the inoculum. The tubes were incubated at 30°C for 48 to 72 h or until growth in the control tube was visible. The reproducibility of the method was quality controlled by testing fluconazole and amphotericin B against C. albicans A39 and C. neoformans var. neoformans H99 in each experiment. The MICs of fluconazole for C. albicans A39 and C. neoformans var. neoformans var. neoformans H99 were 0.25 and 2 g/ml, respectively. The MIC of amphotericin B was 1 g/ml for both isolates.
RESULTS

Carbazoles.
A series of 15 carbazoles (Table 1) were chosen for antifungal screening on the basis of their high levels of activity against P. carinii pneumonia (22) . When the carbazoles were considered as a group, they appeared to have more potent activity against C. neoformans than against C. albicans. Examination of the data from Table 1 indicates that 2,7-substituted analogues (compounds 10, 11, and 12) were significantly more effective than the corresponding 3,6-substituted analogues (compounds 1, 3, and 5) against C. albicans. The only exception to this observation was in the increased activity of the 3,6-benzimidazole-substituted carbazole (compound 9) compared to the activity of the corresponding 2,7-substituted analogue (compound 13). In compounds 9 and 13 the distance separating the cationic moieties is greatly increased, and these compounds cannot be compared structurally with analogues having the cationic groups attached directly to the carbazole ring. The most potent carbazole against C. albicans was compound 10, which had an MIC of 0.78 g/ml and an MFC of 1.56 g/ml. The MIC of this compound was in the same range as that of fluconazole. Several of the carbazole derivatives were found to have activities against C. neoformans comparable to those of the control drugs. The only dicationic carbazole devoid of activity at 100 g/ml against C. neoformans was the analogue with an isopropyl group-substituted amidine (compound 4). The most potent derivatives were compounds with imidazolines as the cationic groups (compounds 3, 5, 6, 11, and 12). It is important that replacement of one of the cationic moieties with a methoxy group resulted in a significant reduction or loss of antifungal activity against both organisms (compounds 14 and 15).
Furans. The series of compounds in which the cationic moieties were substituted in the para position on a phenyl ring attached to a 2,5-furanyl bridge (Table 2) was also selected for testing against fungi on the basis of the excellent anti-pneumocystis activities exhibited by selected members of the class (5, 6) . Several members of this series exhibited good activity against C. albicans, but none of the compounds were found to have activity equal to or better than that of amphotericin B or fluconazole. Ten of the compounds in this series were devoid of activity against C. albicans at the highest dose tested (100 g/ml). This series exhibited greater potency against C. neoformans than against C. albicans, with the MICs of four of the compounds (compounds 20, 21, 23, and 31) being lower than the MICs of the control drugs. The MIC of the most potent compound of the series (compound 31) against C. neoformans was more than 10 times greater than that of amphotericin B and 20 times greater than that of fluconazole. The only compounds devoid of activity against C. neoformans were the compounds with an amido moiety (compounds 33 to 37) and a compound with methoxy group-substituted amidines (compound 18).
The meta analogues of the compounds described above (Table 3) exhibited only modest or no activity against C. albicans. A significant increase in activity is noted for the para-substituted compounds over the meta-substituted analogues (compare compounds 16 and 38 and compounds 25 and 40). The meta analogues are more potent against C. neoformans than against C. albicans. Against C. neoformans the meta analogues were as potent or slightly more potent than their para counterparts.
Like the compounds described above, those in Table 4 have the furan ring in the bridge between the cation-containing rings. However, these compounds are asymmetrical and have one cation on a benzimidazole ring, while the second cation is attached to a phenyl ring. Only two of these compounds (compound 43 and 45) exhibited significant activity against C. albicans. All five of the compounds of this series had good activity against C. neoformans. The two most potent compounds against C. neoformans (compounds 43 and 45) were the only two structures showing significant activity against C. albicans. Benzimidazoles. The compounds depicted in Table 5 are all characterized by having a 2-phenylbenzimidazole as the central linker between the cationic moieties. Molecules in this group have previously been studied for their DNA minor groove binding (8, 9) and protease inhibition (25) properties. Because we have associated the ability of these molecules to bind in the minor groove of DNA with their antimicrobial activity (1, 24) , compounds 48 to 63 were logical choices for antifungal testing. In addition to being studied for antitrypsin potency, compounds 64 to 67 were determined to be excellent DNA binding agents and to have potent anti-P. carinii activities (23a). Eleven of the compounds in this series were found to have activity against C. albicans approaching the same level as those of amphotericin B and fluconazole. The MICs of three of the compounds (compounds 53, 64, and 65) for C. albicans were 0.39 g/ml. Ten of the compounds in this group had potencies equal to or greater than those of the control drugs against C. neoformans, with two compounds (compounds 53 and 65) exhibiting a 10-fold greater potency than amphotericin B. In addition, seven compounds (compounds 53, 54, 56, and 64 to 67) demonstrated excellent activity against both fungi compared to the activities of amphotericin B and fluconazole.
Broad-spectrum activities of compounds 10, 21, and 53. Three compounds were selected for extended in vitro susceptibility testing to determine their spectra of antifungal activity. Compound 10 was chosen as an example of the carbazole group on the basis of the excellent activity of the compound against P. carinii (22) and Cryptosporidium parvum (3) and the low level of toxicity of the compound in rats (22) . Compound 21 was chosen on the basis of its good in vitro activity against C. albicans and C. neoformans and the availability of the compound. Compound 53 was chosen from the benzimidazole group because of its excellent activity against C. albicans and C. neoformans. The compounds were tested against Candida strains other than C. albicans including fluconazole-resistant isolates, several C. neoformans isolates including serotype B and C isolates, and some clinically important molds. All three compounds exhibited broad-spectrum activity (Table 6 ). Compound 10 was active against all strains of Candida and Cryptococcus tested, with excellent potency against C. tropicalis. Compound 10 showed good activity against A. fumigatus but only modest activity against A. flavus, F. solani, P. lilacinus, and R. arrhizus. Compound 21 showed a pattern of activity very similar to that of compound 10. A notable difference between the two compounds was that compound 10 tended to be more effective against Candida strains, while compound 21 exhibited more potency toward Cryptococcus strains. Compound 21 was observed to be active against fluconazole-resistant strains of C. albicans. Compound 53 showed excellent activity against all strains tested with the exceptions of A. flavus, P. lilacinus, and R. arrhizus. This compound was highly potent against A. fumigatus and F. solani and all strains of Cryptococcus and Candida.
DISCUSSION
The antifungal data from Tables 1 to 5 indicate that a number of the 67 compounds tested exhibit activities equal to or greater than those of fluconazole and amphotericin B. As we reported earlier (11) , this class of compounds is not only inhibitory but also shows in vitro fungicidal activity.
In addition to the activities of the compounds against several isolates of C. neoformans and C. albicans, it was encouraging to (5, 6, 8, 22) with the corresponding antifungal activity reveals no direct correlation between affinity for the minor groove of DNA and their antifungal activities. However, the only compounds in this series that did not bind in the minor groove of DNA (compounds 14 and 15) (22) were also devoid of antifungal activity at the highest dose tested, 100 g/ml. These data are supportive of our hypothesis that minimal DNA binding is necessary for, but not an assurance of, antimicrobial activity (22) . We have theorized that the binding of compounds to the DNA results in competitive inhibition of key DNAdirected enzymes. Therefore, the strength of DNA binding is not as important as the site of binding in the minor groove (2, 11, 22) . Previously, we had reported that there was a strong correlation between the antigiardial activity of dicationic molecules and their ability to bind in the minor groove and to inhibit topoisomerase II (2) . Our present data suggest that topoisomerase I is probably not the target of these compounds in C. neoformans, as for camptothecin and its congeners (12) . It has been hypothesized that the primary cellular target of a dicationic compound, pentamidine, in S. cerevisiae is the mitochondrion (19) , and more recently, it has been suggested that these compounds have an effect on P. carinii due to DNA binding followed by inhibition of an endo-or exonuclease (15) . A key to the further development of these dicationic molecules as antifungal agents will be to establish their mechanisms of action. The ability to readily grow these fungi in vitro compared to the ability to grow giardia, cryptosporidium, and pneumocystis in vitro bodes well for future studies into determining the mechanism(s) of antifungal activity of these dicationic molecules.
In addition to determining the mechanisms of action of dicationic molecules and developing a rational approach to drug design, lead compounds (i.e., compound 53) will be resynthesized for testing in animal models of fungal disease. If it can be determined that dicationic molecules are effective in vivo, the enthusiasm for this class of compounds as clinically useful antifungal agents will be greatly increased.
